Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Mixed endocrine tumors].

Valérie Hervieu1, Jean-Yves Scoazec

  • 1Service Central d'Anatomie et Cytologie Pathologiques, Hôpital Edouard Herriot, 3 place d'Arsonval, 69437 Lyon cedex.

Annales De Pathologie
|June 1, 2006
PubMed
Summary

Mixed endocrine tumors, rare and complex, present diagnostic and therapeutic challenges. Management strategies depend on the most aggressive tumor component for optimal patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

[Mucinous carcinomas across organs: Definitions, profiles, diagnostic pitfalls and practical implications for pathologists].

Annales de pathologie·2026
Same author

Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers.

Nature communications·2026
Same author

Cytokines released by human tumors are independent from cancer histotype.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Oncogenic PIK3CA mutations shape an immunoregulatory microenvironment in mosaic overgrowth disorders.

PNAS nexus·2026
Same author

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Nature·2026
Same author

Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.

Nature·2026

Area of Science:

  • Oncology
  • Pathology
  • Endocrinology

Context:

  • Mixed endocrine tumors comprise at least two distinct neoplastic populations, with one being endocrine.
  • Their rarity and varied presentations complicate diagnosis, management, and therapy.
  • Molecular studies confirm diverse types but cannot predict histogenesis from histological features alone.

Purpose:

  • To review the classification, diagnosis, and management of mixed endocrine tumors.
  • To highlight diagnostic challenges, especially differentiating components and identifying poorly differentiated endocrine cells.
  • To outline therapeutic principles based on the most aggressive tumor component.

Summary:

  • Composite tumors are the most common mixed endocrine tumors, with the WHO recommending specific criteria for their definition.
  • Immunodetection of endocrine and neuroendocrine markers (e.g., chromogranin A, synaptophysin) is crucial for confirming the endocrine component, particularly when poorly differentiated.
  • These tumors can arise in various anatomical sites, both endocrine-rich organs like the pancreas and endocrine-devoid sites such as the mammary gland.

Impact:

  • Accurate diagnosis and classification are essential for appropriate treatment selection.
  • Understanding the behavior of the most aggressive component guides therapeutic decisions, impacting patient prognosis.
  • This review aids clinicians in managing these challenging neoplasms, improving patient care and outcomes.

Related Experiment Videos